KGKelly J. Gaffney

Kelly J. Gaffney

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Kelly J. Gaffney has a total of 57 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Impact of age, obesity, and renal impairment on outcomes after autologous stem cell transplantation for patients with newly diagnosed multiple myeloma

    by Kelly J Gaffney, Jonathan K. Bakos, Arash Velayati, James A. Davis, Aswani Thurlapati, Erin Weeda, Andy Maldonado, Katelynn Granger, Coleen Butcher, Taylor Herrington, et al.

    Introduction: There remains a need to determine whether certain subgroups of newly diagnosed multiple myeloma (NDMM) derive the same benefit from high-dose chemotherapy–autologous stem cell transplant (HDT-ASCT). We describe our institutional experience highlighting the impact of age, obesity, and renal impairment on outcomes after HDT-ASCT for patients with NDMM in a real-world setting. Methods: A total of 449 consecutive patients were included in this retrospective analysis. Results: No difference in median progression free survival or overall survival was seen for patients with age > 65, body mass index (BMI) > 30 kg/m2, or estimated glomerular filtration rate < 60 mL/min/1.73 m2 when compared to those without these characteristics. From a safety standpoint, there were no differences in the incidence of transplant-related mortality or secondary malignancy among subgroups. Conclusion: For patients with NDMM undergoing HDT-ASCT, there is no difference in outcomes based on age, BMI, or renal function, and the presence of one or more of these factors should not preclude patients from HDT-ASCT.

  • Early cytopenias and infections following chimeric antigen receptor T-Cell therapy for hematologic malignancies

    by Mary McGann, Arash Velayati, Kiera Roubal, Katelynn Granger, James A. Davis, Kelly J. Gaffney, Erin Weeda, Hamza Hashmi


  • Open Access

    Impact of Age, Obesity, and Renal Impairment on Outcomes After Autologous Stem Cell Transplantation for Patients with Newly Diagnosed Multiple Myeloma

    by Kelly Gaffney, Jonathan Bakos, Arash Velayati, James Davis, Aswani Thurlapati, Erin Weeda, Andy Maldonado, Katelynn Granger, Coleen Butcher, Taylor Herrington, et al.

    Introduction: High-dose chemotherapy-autologous stem cell transplant (HDT-ASCT) improves both depth and duration of remission for patients with transplant-eligible newly diagnosed multiple myeloma (NDMM). Whether certain subgroups of NDMM derive the same benefit from HDT-ASCT remains unclear. We describe our institutional experience highlighting the impact of age, obesity, and renal impairment on outcomes after HDT-ASCT for patients with NDMM in a real-world setting. Methods: A total of 449 consecutive patients with NDMM treated with HDT-ASCT between February 2012 and August 2022 were included in this retrospective analysis. All patient, disease, and transplant-related data were obtained by chart review of an institutional review board approved myeloma database. Responses to therapy were evaluated per International Myeloma Working Group uniform response criteria. Survival analyses including progression free survival (PFS) and overall survival (OS) were performed using Kaplan-Meier method. Results: Nearly one-third of the patients (n = 154, 34%) were above the age of 65 at the time of transplant. Forty six percent of the patients had a body mass index (BMI) equal to greater than 30 kg/m2 (n = 205). A vast majority of patients had a normal renal function with 16% (n = 72) having estimated glomerular filtration rate (eGFR) less than 60 ml/min/1.73 m² at the time of transplant. Median follow up for the entire patient population was 29 (1-129) months. When comparing efficacy outcomes across these subgroups, no difference in median PFS was seen for patients with age > 65 (66 versus (vs) 59 months, p=0.46), BMI >30 kg/m2 (91 vs 53 months, p=0.1), or eGFR 65 (91 vs not reached (NR) months, p=0.69), BMI >30 kg/m2 (NR vs 104 months, p=0.36), or eGFR mL/min/1.73 m2 (NR vs NR months, p=0.25) when compared to those without these characteristics. From a safety standpoint, there were no differences in the incidence of transplant related mortality or secondary malignancy among these subgroups. On multivariable analysis, eGFR less than 60 mL/min/1.73 m2 was the only risk factor significantly associated with superior PFS (hazard ratio 0.581, confidence interval 0.355-0.954). Conclusion: For patients with NDMM undergoing HDT-ASCT, there is no difference in outcomes based on age, BMI, or renal function, and the presence of one or more of these factors should not preclude patients from HDT-ASCT.

  • Early versus standard management of chimeric antigen receptor therapy toxicities and management's impact on safety and efficacy

    by Kelly J Gaffney, James A Davis, Mary McGann, Kathy Edwards, Zaheer Ahmed, Colleen Butcher, Brian Greenwell, Brian T Hess, Hamza Hashmi

    Background: Cytokine release syndrome (CRS) and immune effector cell-associated neurologic syndrome (ICANS) are well-documented toxicities of CAR T-cell therapy. To mitigate excessive toxicity, our center has formulated treatment protocols (early vs. standard) for timely management of CRS and ICANS with tocilizumab and/or corticosteroids. Methods: This retrospective, single-center analysis included patients treated with CAR T-cell therapy. The goal was to describe the association of two management protocols with toxicity and efficacy outcomes. Results: Fifty-five percent of the 40 patients assigned to early management, out of which 5% and 9% developed grade 3+ CRS and ICANS, respectively. Seventy-seven percent and 41% of these patients received tocilizumab and corticosteroids, respectively. Forty-five percent of patients were stratified as standard management, out of which 0% and 11% developed grade 3+ CRS and ICANS, respectively. Seventeen percent and 28% of these patients received tocilizumab and corticosteroids, respectively. The day +90 overall response rate (ORR) for all patients was 63%, with an ORR of 89% for those managed per early management versus 50% for those managed per standard protocol. Conclusion: Early use of tocilizumab and corticosteroids is effective in preventing excessive CAR-T-related toxicities with no negative impact on efficacy.


  • Open Access

    Stem Cell Mobilization for Multiple Myeloma Patients Receiving Daratumumab-Based Induction Therapy: A Real- World Experience

    by Aswani Thurlapati, Kiera Roubal, James A. Davis, Syed Z. Shah, Deidra Smith, Mary McGann, Kelly Gaffney, Alyssa Cendagorta, Andy Maldonado, Erin Weeda, et al.


  • Newly approved and forthcoming T-cell-redirecting bispecific antibodies for the treatment of relapsed/refractory multiple myeloma

    by Katelynn Granger, Kelly J Gaffney, James A Davis

    Objective: Summarize the background, clinical trials, and place in therapy for the newly Food and Drug Administration (FDA) approved and forthcoming bispecific antibodies for relapsed/refractory (R/R) multiple myeloma. Data Sources: A search of the PubMed database was conducted using the following search terms: B-cell maturation antigen (BCMA), teclistamab, myeloma, BsAbs, GPRC5D, and bispecific. Ongoing clinical trials as well as abstracts from ASH and ASCO evaluating the efficacy and safety of novel agents were evaluated. Prescribing information was also reviewed. Summary: For patients with R/R multiple myeloma who have failed available therapies, treatment options are limited and survival is short. The FDA recently approved teclistamab, a T-cell-redirecting bispecific antibody, in patients with R/R multiple myeloma who have failed four prior lines of therapy. Teclistamab targets both CD3 expressed on T-cells and BCMA expressed on the surface of myeloma cells, mediating T-cell activation and lysis of plasma cells that express BCMA. Accelerated approval was granted based upon the results of the MajesTEC-1 study, which showed a durable response in a high proportion of heavily pretreated patients. Teclistamab is the first bispecific antibody approved for use in patients with multiple myeloma and the fourth approved agent targeting BCMA. Additional T-cell redirecting bispecific antibodies for use in multiple myeloma are also currently being studied. Conclusion: Teclistamab is the newest agent granted FDA approval for use in R/R multiple myeloma and represents a promising new option for patients. Ongoing trials are investigating teclistamab and other novel bispecific antibodies in the upfront and R/R setting.


  • Open Access

    Prophylactic Trimethoprim-Sulfamethoxazole for Allogeneic Hematopoietic Stem Cell Transplant Recipients During the Pre-engraftment Period

    by Kelly J. Gaffney, Theresa A. Urban, Mariana Lucena, Lisa Rybicki, Navneet S. Majhail, Sherif Beniameen Mossad

    Background: Our institution has used trimethoprim-sulfamethoxazole (TMP-SMX) as the antibacterial agent of choice for infection prophylaxis during the pre-engraftment period in the allogeneic transplant (allo-HCT) population. Methods: This retrospective, single center study was developed to compare the safety of that antibacterial prophylaxis to fluoroquinolones in allo-HCT. The primary endpoint was time to neutrophil engraftment. Results: A total of 366 patients were reviewed (TMP-SMX n = 332, fluoroquinolone n = 34). No difference in days to neutrophil engraftment was found (median 15 versus 16 days, p = 0.62). Hyperkalemia was more common in the TMP-SMX cohort (32.2% versus 14.7%, p = 0.035); this did not contribute to a higher rate of agent discontinuation or arrhythmia. There was no significant difference in the incidence of neutropenic fever; however, those in the TMP-SMX cohort were more likely to have microbiologically confirmed bacteremia (24.1% versus 8.8% respectively, p = 0.043). There was no significant difference in infections. No long-term implication of prophylactic antibacterial agent selection was observed in terms of graft-versus-host-disease, underlying disease relapse, or mortality. Conclusion: The use of TMP-SMX was associated with a higher likelihood of bacteremia and hyperkalemia; however, this did not result in increased hospital stay, escalation of care, or mortality. The use of TMP-SMX for prophylaxis during the pre-engraftment period for allo-HCT recipients is safe and effective.


  • The incidence and characteristics of VTE within 100 days of CAR T-cell therapy

    by Kelly J. Gaffney, Mary McGann, James A. Davis, Kathy H. Edwards, Hamza Hashmi

  • Open Access

    Efficacy of tixagevimab-cilgavimab in preventing SARS-CoV-2 for patients with B-cell malignancies

    by James A. Davis, Katelynn Granger, Kiera Roubal, Deidra Smith, Kelly J. Gaffney, Mary McGann, Alyssa Cendagorta, Aswani Thurlapati, Amanda Herbst, Lindsey Hendrickson, et al.

    COVID-19 still represents a major issue for patients with lymphoid malignancies, especially those on therapy, because of immune suppression and suboptimal responses to vaccination. Davis et al report on their experience with double dose tixagevimab-cilgavimab preexposure prophylaxis in a cohort of 251 patients with chronic lymphocytic leukemia, B-cell lymphomas, multiple myeloma, or B-cell acute lymphoblastic leukemia, 63% of whom had received 3 doses of the SARS-CoV-2 vaccine. Breakthrough infections within 3 months occur despite passive immunization, affecting 11% in this series; however, hospitalization rates are low, and mortality was avoided, suggesting benefit from this strategy.


  • Fever Characteristics and Impact on Safety and Efficacy of Chimeric Antigen Receptor T-Cell Therapy

    by James A. Davis, Kelly J. Gaffney, Mary McGann, Deidra Smith, Kathy Edwards, Ellen Baldino, Keegan Bakos, Coleen Butcher, Brian Greenwell, Brian T. Hess, et al.